UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2024
Commission File Number: 001-36815
Ascendis Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Tuborg Boulevard 12
DK-2900 Hellerup
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Spokespersons of Ascendis Pharma A/S (the “Company”) plan to present the information in the presentation slides attached hereto as Exhibit 99.1 at various investor and analyst meetings scheduled during the week of January 8, 2024.
The furnishing of the attached presentation and press release is not an admission as to the materiality of any information therein. The information contained in the presentation and press release is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company has made and may make from time to time. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing or furnishing of other reports or documents with the SEC or through other public disclosures.
Exhibits
| 99.1 | Company Presentation dated January 8, 2024. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Ascendis Pharma A/S | ||||||
| Date: January 8, 2024 | By: | /s/ Michael Wolff Jensen | ||||
| Michael Wolff Jensen | ||||||
| Executive Vice President, Chief Legal Officer | ||||||
Ascendis Pharma A/S 42nd Annual J.P. Morgan Healthcare Conference January 8, 2024 For investor communication only. Not for use in product promotion. Not for further distribution. Exhibit 99.1
Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding our products and prospective product candidates; clinical trial results; the expected timing of future clinical trial results and feedback from regulatory authorities; the scope, progress, results and costs of developing our product candidates or any other future product candidates; timing and likelihood of success; plans and objectives of management for future operations and commercialization activities; and future results of current and anticipated products and product candidates are forward-looking statements. These forward-looking statements are based on our current expectations and beliefs, as well as assumptions concerning future events. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties and other factors are more fully described in our reports filed with or submitted to the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 20-F filed with the SEC on February 16, 2023 particularly in the sections titled “Risk Factors” and “Operating and Financial Review and Prospects.” In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. Any forward-looking statement made by us in this presentation speaks only as of the date of this presentation and represents our estimates and assumptions only as of the date of this presentation. Except as required by law, we assume no obligation to update these statements publicly, whether as a result of new information, future events, changed circumstances or otherwise after the date of this presentation. This presentation concerns Ascendis Pharma approved products as well as Ascendis Pharma investigational product candidates that are or have been under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency or other foreign regulatory authorities. These investigational product candidates are currently limited by law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated. This presentation is for investor communication only. Not for use in product promotion. For investor communication only. Not for use in product promotion. Not for further distribution.
Executive Summary Validated TransCon technology platform and algorithm for product innovation Two approved products – SKYTROFA® (TransCon hGH) and YORVIPATH® (TransCon PTH) Pivotal data and submission of NDA for TransCon CNP expected in Q4 2024 Oncology portfolio Phase 2 data expected in Q4 2024 Creation of Ophthalmology NewCo, financed by institutional investors, expected in Q1 2024 SKYTROFA achieved U.S. market value leadership in 2023 Expected full year 2023 SKYTROFA revenue of ~€179 million1 Full year 2024 SKYTROFA revenue expected to be €320 to €340 million2 YORVIPATH® first launch in Germany January 2024 Rolling out to Europe Direct and International Markets starting in 2024 In the U.S., PDUFA goal date of May 14, 2024, and launch expected the following quarter, if approved Business model built on fast, successful drug development and commercial therapeutic synergies Expect to be operating cash flow breakeven on a quarterly basis by the end of 2024 For investor communication only. Not for use in product promotion. Not for further distribution. 1 Unaudited preliminary estimate. 2 Based on average 2023 exchange rates.
Vision 3x3: Building a Leading Global Biopharma Company Our goal is to achieve sustainable growth through multiple approaches Obtain regulatory approval for three independent Endocrinology Rare Disease products TransCon™ hGH for pediatric growth hormone deficiency TransCon™ PTH for adult hypoparathyroidism TransCon™ CNP for achondroplasia Grow Endocrinology Rare Disease pipeline through Global clinical reach Pursuing 9 total indications, label optimization, and life cycle management New endocrinology products Establish global commercial presence for our Endocrinology Rare Disease area Build integrated commercial organization in North America and select European countries Establish global commercial presence through partners with local expertise and infrastructure Advance a high-value oncology pipeline with one IND or similar filing each year Create a third independent therapeutic area with a diversified pipeline Ascendis Pharma’s 2020 - 2025 strategic roadmap For investor communication only. Not for use in product promotion. Not for further distribution.
Endocrinology Rare Disease Pipeline & Ascendis Direct Commercialization For investor communication only. Not for use in product promotion. Not for further distribution.
Endocrinology Rare Disease Products Approved in Major Markets TransCon hGH Pediatric Growth Hormone Deficiency United States1 Approved in the U.S. as SKYTROFA (lonapegsomatropin-tcgd) European Union2 and Selected Other Countries3 Approved in the EU as SKYTROFA (lonapegsomatropin) TransCon PTH Adult Chronic Hypoparathyroidism European Union4 and Selected Other Countries5 Approved in the EU as YORVIPATH (palopegteriparatide) First country launch planned in Germany in January 2024 1. SKYTROFA® [package insert]. Palo Alto, CA: Ascendis Pharma Inc. October 2022. 2. SKYTROFA® SMPC. Hellerup, Denmark: Ascendis Pharma Inc. January 2022. 3. SKYTROFA® is also approved in Norway, Iceland, Lichtenstein and Great Britain (covering England, Wales, Scotland). 4. YORVIPATH® SMPC. Hellerup, Denmark: Ascendis Pharma Inc. November 2023. 5. YORVIPATH® is also approved in Norway and Iceland. For investor communication only. Not for use in product promotion. Not for further distribution.
TransCon hGH: Expanding Beyond Pediatric GHD Pediatric GHD accounts for approximately 50% of the hGH market by patients Growth hormone plays an essential role in the health of children and adults Maintains normal body composition and cardiometabolic health Promotes normal growth in children Daily hGH is approved for multiple indications in adult and pediatric patients Adult GHD accounts for approximately 10% of the daily hGH market However, fewer than 10% of adults with suspected GHD1 are treated with hGH TransCon hGH Phase 3 foresiGHt Trial in adult GHD Demonstrated superiority to placebo on primary and secondary efficacy endpoints Demonstrated comparable results to daily hGH on primary and secondary endpoints2 Expected sBLA submission in Q2 2024 For investor communication only. Not for use in product promotion. Not for further distribution. 1 A. Hoffman et al (2023). SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency. Journal of the Endocrine Society. 7. 10.1210/jendso/bvad114.1344. 2 Exploratory post-hoc analysis for patients with IGF-1 SDS levels ≤ 1.75 at Week 38.
SKYTROFA Revenue Development and Expectations SKYTROFA was launched in U.S. in Q4 2021, Germany in Q3 2023 SKYTROFA Q4 2023 revenue of ~€64 million* Estimated SKYTROFA U.S. pediatric GHD market penetration exiting 2023 at ~16% Expect full year 2024 SKYTROFA revenue of €320 - €340 million** * Unaudited preliminary estimate. ** Reflects 2024 SKYTROFA revenue expectations announced on Jan. 7, 2024, based on average 2023 exchange rates. For investor communication only. Not for use in product promotion. Not for further distribution. Quarterly SKYTROFA Revenue (million) Annual SKYTROFA Revenue (million)
TransCon hGH Program Summary and Outlook Attained U.S. market value leadership in 2023 Completed enliGHten Trial in pediatric GHD1 Majority of patients met or exceeded average parental height SDS Demonstrated the long-term safety in patients treated up to 6 years Planned sBLA submission to FDA for adult GHD Q2 2024 Topline results from Phase 2 trial in Turner syndrome expected Q4 2024 Expanding reach for SKYTROFA through Ascendis commercial organization building on therapeutic synergies Full year 2024 SKYTROFA revenue expected to be €320 to €340 million2 For investor communication only. Not for use in product promotion. Not for further distribution. Committed to making TransCon hGH the global leading product in value in a growing growth hormone market 1 Vlachopapadopoulou et al. Poster LB17, presented at ESPE 2023. 2 Based on average 2023 exchange rates.
Myopathy Spondylorthropathy Dry skin Thinning hair Brittle nails Altered tooth morphology Cataracts Papilledema Anxiety & depression Cognitive impairment (“brain fog”) Paresthesia Muscle cramps Pain Tetany Nephrocalcinosis* Nephrolithiasis* Chronic kidney disease* Vascular calcifications Cardiac arrhythmias Hypocalcemia-associated dilated cardiomyopathy Laryngospasm Seizures Basal ganglia calcifications Parkinsonism or dystonia Hypoparathyroidism: One Disease, Multiple Consequences1-4 CENTRAL NERVOUS SYSTEM OPHTHALMALOGICAL PERIPHERAL NERVOUS SYSTEM CARDIOVASCULAR DERMATOLOGICAL RENAL NEUROPSYCHIATRIC MUSCULOSKELETAL DENTAL RESPIRATORY Thyroid gland Parathyroid gland Absence or deficiency of parathyroid hormone (PTH) is linked to multi-organ manifestations5,6 * These manifestations are mostly the result of treatment with calcium supplements and activated vitamin D rather than of the disease itself.5 1. Underbjerg L, Sikjaer T, Mosekilde L, et al. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28(11):2277-2285. doi:10.1002/jbmr.1979. 2. Underbjerg L, Sikjaer T, Mosekilde L, et al. The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res. 2015;30(9):1738-1744. doi:10.1002/jbmr.2501. 3. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016;101(6):2300-2312. doi:10.1210/jc.2015-3909. 4. Underbjerg L, Sikjaer T, Mosekilde L, et al. The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res. 2015;30(9):1738-1744. doi:10.1002/jbmr.2501. 5. Mannstadt M, Bilezikian JP, Thakker RV, et al. Hypoparathyroidism. Nat Rev Dis Primers. 2017;3:17055. doi:10.1038/nrdp.2017.55. 6. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016;101(6):2300-2312. doi:10.1210/jc.2015-3909. For investor communication only. Not for use in product promotion. Not for further distribution.
Latest Clinical Practice Guideline Consider PTH replacement therapy in patients not adequately controlled on conventional therapy Inadequate control is considered to be any one of the following: Symptomatic hypocalcemia Hyperphosphatemia Renal insufficiency Hypercalciuria Poor quality of life In addition, individuals with poor compliance, malabsorption, or who are intolerant of large doses of calcium and active vitamin D may also benefit from PTH replacement therapy 1. Aliya A Khan et al, The Second International Workshop on the Evaluation and Management of Hypoparathyroidism, Journal of Bone and Mineral Research, 10.1002/jbmr.4671. For investor communication only. Not for use in product promotion. Not for further distribution.
Significantly Improved Renal Function with TransCon PTH Treatment in Phase 3 PaTHway Trial Post Hoc Analysis eGFR (an assessment of kidney filtering capacity) was calculated by the trial’s central lab using the Modification of Diet in Renal Disease Study Group (MDRD) equation (Levey, Ann Intern Med 2006). Patients Randomized to TransCon PTH Change in mean eGFR from Baseline (mL/min/1.73m) Patients Randomized to Placebo / Switched to TransCon PTH after Week 26 At Week 26 At Week 26 At Week 52 At Week 52 eGFR < 60 at baseline eGFR ≥ 60 at baseline For investor communication only. Not for use in product promotion. Not for further distribution. ▲ ▲ ▲ ▲ * * * indicates nominal p<0.05 ▲ indicates nominal p<0.001 Data on file.
Europe Direct1 – Germany ~70,000 adults2 with chronic hypoparathyroidism in Germany Launch of YORVIPATH planned in January 2024, initial list price3 of €105,000 per patient per year Europe Direct – other selected countries Over 100,000 additional adults with chronic hypoparathyroidism Next major market expected end of 2024, expected availability across Europe by end of 2025 Providing commercial product through early access routes, such as ‘named patient,’ until commercial reimbursement established U.S. Over 80,0004 adults with chronic hypoparathyroidism in the U.S. PDUFA date May 14, 2024; expect to launch in Q3 2024, if approved Experienced commercial team in place for rapid, efficient launch Ascendis Commercial Organization - TransCon PTH Launch For investor communication only. Not for use in product promotion. Not for further distribution. 1 DACH, France & BeNeLux, Iberia, Italy, Nordics, UK & Ireland. 2 German SHI claims data from the Institute for Applied Health Research Berlin (Institut für angewandte Gesundheitsforschung Berlin - InGef) research database. 3 Herstellerabgabepreis. 4 U.S. prevalence literature review and epi meta-analysis (Powers, Clarke, Milliman project, ipm.ai claims project; HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. for surgical cohort projection).
TransCon PTH Program Summary and Outlook Completed two successful Phase 3 trials: PaTHway and PaTHway Japan Post hoc analysis showed significantly improved renal function in TransCon PTH-treated patients Approved in European Union and other territories as YORVIPATH German launch of YORVIPATH planned in January 2024 Rolling out to Europe Direct and International Markets starting in 2024 In the U.S., PDUFA date of May 14, 2024 U.S. launch of YORVIPATH expected in Q3 2024, if approved Launching TransCon PTH through established, proven endocrinology rare disease infrastructure For investor communication only. Not for use in product promotion. Not for further distribution.
Current Consensus Updated View Changing the Treatment Paradigm of Achondroplasia Primary Manifestations Secondary Manifestations Growth disorder Growth disorder Muscle disorder Height ACH-AE HRQoL Muscle Strength/ Stamina Height ACH-AE ACH-AE; Increased incidence of Achondroplasia-related Adverse Events. HRQoL: Reduced Health-Related Quality of Life; Height; Reduced height. Muscle Strength/Stamina; Reduced muscular functionality, including reduced strength and stamina Address all aspects of achondroplasia for patients of all ages HRQoL Muscle Strength/ Stamina direct consequence indirect/secondary consequence For investor communication only. Not for use in product promotion. Not for further distribution. TransCon CNP is an investigational product candidate.
Growth across full trial population (n=57) on TransCon CNP 100 µg/kg/week for 52 weeks consistent with results from randomized period ANCOVA model. Data on file. Treatment Effect of TransCon CNP 100 µg/kg/week, Age 2-10 years TransCon CNP Blinded Period Placebo TransCon CNP Blinded Period Placebo TransCon CNP incl 1-year OLE 6 mg/kg/week 20 mg/kg/week 50 mg/kg/week 100 mg/kg/week Pooled Placebo 100 mg/kg/week (All ages) 6 mg/kg/week 20 mg/kg/week 50 mg/kg/week 100 mg/kg/week Pooled Placebo 100 mg/kg/week (All ages) N= AHV (cm/Year) TransCon CNP incl 1-year OLE 10 11 15 57 N= 10 11 10 11 10 11 15 57 TransCon CNP is an investigational product candidate. ACH Height SDS D For investor communication only. Not for use in product promotion. Not for further distribution. AHV: Annualized height velocity; ACH: achondroplasia; SDS: standard deviation score; OLE: open-label extension.
Health-Related Quality-of-Life Measures (HRQoL) SF-10™ Health Survey for Children A 10-item non-disease specific survey of a child’s functional health and well-being.1 Physical measures include assessments of: Limitations in activities, schoolwork Bodily pain or discomfort Overall health relative to other children Physical coordination or clumsiness Lower scores indicate greater impairment. Validated in children ages 5 yrs and older. Achondroplasia Child Experience Measure A condition-specific clinical outcome measure that assesses the impact of achondroplasia on a child’s health-related quality of life. Includes assessments of:2 Daily Living – Reach objects or high places. Toilet themselves. Bath, shower, wash. Perform fine motor skill tasks. Emotional Well-Being – Feeling different, frustrated, etc. Physical Functioning – Sit for long periods of time. Climb stairs. Be physically active. Walk long distances. Run. School – Difficulty participating. Limited or modified gym class participation. Missed school. The measure is scored on a 0-100 scale, with higher scores indicating greater impairment. 1. SF-10 Health Survey for Children™ | QualityMetric Accessed 28 December 2023. 2. ACEM-Impact | Achondroplasia Child Experience Measure - Impact described in ePROVIDE (mapi-trust.org) Accessed 28 December 2023. For investor communication only. Not for use in product promotion. Not for further distribution. TransCon CNP is an investigational product candidate.
Achondroplasia Child Experience Measure Consistent Positive Treatment Effect Across HRQoL Domains SF-10 Physical Summary LS mean difference to placebo (95%CI) by ANCOVA LS mean difference to placebo (95%CI) by ANCOVA Placebo better 100µg/kg better Placebo better 100µg/kg better Placebo n= 100 µg/kg/week n= 13 14 5 9 13 16 9 13 13 16 6 12 p=0.002 p=0.047 p=0.045 Patients dosed with TransCon CNP demonstrated HRQoL improvements in multiple domains compared to placebo TransCon CNP is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. All participants in blinded or OLE period of ACcomplisH who were initiated directly on 100µg/kg/week treatment (total n=19) compared to all participants from blinded period receiving placebo (n=15). All domains are missing some data points. Nominal p-values. Data on file.
TransCon hGH / CNP Combination Trial - COACH Trial Phase 2 open-label, single-arm trial (age 2-11 years), Clinical Trial Application (CTA) submitted Primary objectives: evaluate treatment effect on linear growth and safety Secondary objectives: evaluate treatment effect on quality of life, radiological endpoints, physical functioning, and body composition Clinical design Cohort A: treatment naïve (n=12) Cohort B: prior treatment with TransCon CNP (100 mg/kg/week) for at least 1 year (n=6) Treatment with TransCon CNP (100 mg/kg/week) and TransCon hGH (0.30 mg/kg/week) Interim analysis at 26 Weeks, full analysis at 52 Weeks Week 26 topline AHV data expected Q4 2024 For investor communication only. Not for use in product promotion. Not for further distribution. TransCon CNP is an investigational product candidate.
TransCon CNP Program Summary and Outlook Pediatric patients: Topline data from pivotal ApproaCH Trial expected Q4 2024 COACH Trial (hGH/CNP combination) Week 26 topline data expected Q4 2024 Plan to submit NDA to FDA in Q4 2024 for the treatment of achondroplasia Infant patients (age 0-2 years) CTA submitted: 52-week randomized, double-blind, placebo-controlled trial Primary endpoints: incidence of TEAEs and change in length/height Z-score Adult patients: IND or similar for trial in adults with achondroplasia planned for Q4 2024 For investor communication only. Not for use in product promotion. Not for further distribution. TransCon CNP is an investigational product candidate. TransCon CNP treatment goal to improve linear growth, quality of life, radiological endpoints, physical functioning, and body composition
Global Commercial Presence Through Partners with Local Expertise and Infrastructure For investor communication only. Not for use in product promotion. Not for further distribution.
Growing Commercial Presence – Rest of the World China VISEN has exclusive license agreement for TransCon hGH, TransCon PTH, and TransCon CNP VISEN’s TransCon hGH Phase 3 and TransCon CNP Phase 2 trials completed Japan Teijin has exclusive license agreement for TransCon hGH, TransCon PTH, and TransCon CNP Phase 3 PaTHway Japan Trial completed International Markets for Endocrinology Rare Disease programs Expanding global reach through exclusive distribution agreements with geographic market leaders Three regional agreements established as of January 2024: Specialised Therapeutics Asia Pte Ltd. (Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand and Vietnam) Er-Kim (Central & Eastern Europe and Turkey) Vector Pharma FZCO (Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar, and Bahrain) For investor communication only. Not for use in product promotion. Not for further distribution.
Financial Update & 2024 Selected Milestones For investor communication only. Not for use in product promotion. Not for further distribution.
Financial Update Preliminary unaudited 2023 results SKYTROFA Q4 revenue of ~€64 million; full year 2023 SKYTROFA revenue of ~€179 million Full year 2023 total revenue of ~€267 million Includes $70 million Teijin upfront payment as non-product revenue in Q4 December 31, 2023 cash, cash equivalents, and marketable securities of ~€400 million Full Year 2024 outlook based on current plans Revenue Expect SKYTROFA revenue of €320 to €340 million1 Expect to provide YORVIPATH revenue update during 2024 Operating expenses (SG&A and R&D) expected to be ~€600 million Operating cash flow: expect to be breakeven on quarterly basis by end of 2024 1 Based on average 2023 exchange rates. For investor communication only. Not for use in product promotion. Not for further distribution.
The Year Ahead Selected Milestones Expected in 2024 TransCon hGH Adult GHD Submit sBLA to FDA TransCon PTH Adults with Chronic Hypoparathyroidism FDA decision TransCon PTH Adults with Chronic Hypoparathyroidism U.S. commercial launch TransCon CNP Achondroplasia (age 2-11) Topline data from pivotal ApproaCH Trial Oncology Complete enrollment in Phase 2 HNSCC trial Oncology Clinical update from indication-specific dose expansion cohorts TransCon hGH Turner Syndrome Topline results from Phase 2 trial TransCon CNP Achondroplasia (age 2-11) Submit NDA to FDA TransCon PTH Adults with Chronic Hypoparathyroidism YORVIPATH launch in Germany TransCon CNP / hGH Achondroplasia (age 2-11) Week 26 topline data from COACH Trial TransCon CNP Achondroplasia (adults) Submit IND or similar HNSCC: Head and neck squamous-cell carcinoma For investor communication only. Not for use in product promotion. Not for further distribution. Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Introducing Vision 2030 For investor communication only. Not for use in product promotion. Not for further distribution.
Vision 2030 Be the Leading Endocrinology Rare Disease Company Achieve blockbuster status (>$1B) for TransCon PTH, TransCon hGH, and TransCon CNP through worldwide commercialization Be the leader in Growth Disorders and Hypoparathyroidism, pursuing clinical conditions, innovative LCM and complementary patient offerings Expand pipeline with Endocrinology Rare Disease blockbuster product opportunities Create Value in Additional Therapeutic Areas through Innovative Business Models Obtain accelerated approval in oncology with registrational trials ongoing Pursue TransCon product opportunities in >$5B indications Maximize value creation of these product opportunities through collaboration with therapeutic area market leaders Differentiate with Ascendis Fundamentals Outperform industry drug development benchmarks with Ascendis’ product innovation algorithm Remain independent as a profitable biopharma through lean and flexible ways of working Let our values Patients, Science, Passion drive our decisions to success For investor communication only. Not for use in product promotion. Not for further distribution. Achieve blockbuster status for multiple products and expand our engine for future innovation
Thank you! © 2024 Ascendis Pharma. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, Skytrofa and Yorvipath are trademarks owned by the Ascendis Pharma group. For investor communication only. Not for use in product promotion. Not for further distribution.